

Matti Aapro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8890351/matti-aapro-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84 papers	4,288 citations	31 h-index	65 g-index
96 ext. papers	4,875 ext. citations	5.4 avg, IF	5.52 L-index

#	Paper	IF	Citations
84	Patient blood management in oncology in the Russian Federation: Resolution to improve oncology care.. <i>Journal of Cancer Policy</i> , 2022 , 31, 100315	1	
83	Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO).. <i>European Journal of Cancer</i> , 2022 , 166, 126-133	7.5	2
82	Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. <i>Oncologist</i> , 2021 , 26, e1073-e1082	5.7	4
81	The European Code of Cancer Practice.. <i>Journal of Cancer Policy</i> , 2021 , 28, 100282	1	7
80	Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. <i>Journal of Cancer Education</i> , 2021 , 36, 1124-1128	1.8	3
79	Efficacy of intravenous NEPA, a fixed NK/5-HT receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103143	7	1
78	Essential Role of Patient Blood Management in a Pandemic: A Call for Action. <i>Anesthesia and Analgesia</i> , 2020 , 131, 74-85	3.9	72
77	The clinical training centers fellowships: a European School of Oncology career development program (2013-2019). <i>Future Oncology</i> , 2020 , 16, 1969-1976	3.6	3
76	Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure. <i>BioDrugs</i> , 2020 , 34, 255-263	7.9	8
75	Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. <i>Oncologist</i> , 2020 , 25, e589-e597	5.7	9
74	The impact of the European School of Oncology masterclass in clinical oncology on self-professional development. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102976	7	2
73	Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102798	7	5
72	Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim. <i>BioDrugs</i> , 2019 , 33, 635-645	7.9	4
71	Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective. <i>Future Oncology</i> , 2019 , 15, 1067-1084	3.6	6
70	Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study. <i>European Journal of Cancer Care</i> , 2019 , 28, e13034	2.4	2
69	Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. <i>Leukemia Research</i> , 2019 , 81, 35-42	2.7	6
68	Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). <i>Breast</i> , 2019 , 45, 7-14	3.6	7

67	Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens. <i>Lancet Oncology, The</i> , 2019 , 20, 1482-1485	21.7	1
66	Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (72h): findings from the MONITOR-GCSF study. <i>Supportive Care in Cancer</i> , 2019 , 27, 2301-2312	3.9	6
65	CINV: still troubling patients after all these years. <i>Supportive Care in Cancer</i> , 2018 , 26, 5-9	3.9	33
64	The Impact of Biosimilars in Supportive Care in Cancer. <i>European Oncology and Haematology</i> , 2018 , 14, 20	0.1	4
63	MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis. <i>European Journal of Haematology</i> , 2018 , 100, 241-246	3.8	4
62	Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey. <i>Cancer Reports</i> , 2018 , 1, e1127	1.5	18
61	Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. <i>BMC Cancer</i> , 2018 , 18, 917	4.8	7
60	Anaemia in Cancer Patients 2018 , 319-322		
59	A Practical Approach to Fatigue Management in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017 , 16, 275-285	3.8	22
58	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?. <i>Breast</i> , 2017 , 33, 191-199	3.6	3
57	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. <i>Supportive Care in Cancer</i> , 2017 , 25, 1127-1135	3.9	30
56	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. <i>Supportive Care in Cancer</i> , 2017 , 25, 3295-3304	3.9	43
55	Towards sustainable cancer care: Reducing inefficiencies, improving outcomes A policy report from the All.Can initiative. <i>Journal of Cancer Policy</i> , 2017 , 13, 47-64	1	19
54	Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. <i>European Journal of Cancer</i> , 2017 , 82, 193-202	7.5	21
53	Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study). <i>Journal of Geriatric Oncology</i> , 2017 , 8, 86-95	3.6	16
52	The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer. <i>Biomedicine Hub</i> , 2017 , 2, 29-31	1.3	
51	Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). <i>Supportive Care in Cancer</i> , 2016 , 24, 911-925	3.9	54
50	Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study. <i>Journal of Pain and Symptom Management</i> , 2016 , 51, 987-93	4.8	42

49 Treatment of the Elderly Head and Neck Cancer Patient **2016**, 743-751

48 Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. *New England Journal of Medicine*, **2016**, 374, 1356-67 59.2 201

47 Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program. *Oncologist*, **2016**, 21, 494-502 5.7 12

46 Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. *Oncologist*, **2015**, 20, 450-8 5.7 79

45 Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. *Journal of Pain and Symptom Management*, **2014**, 47, 839-848 4.8 96

44 Modeling of treatment response to erythropoiesis-stimulating agents in older (age ≥ 70 years) and younger (age < 70 years) patients. *Journal of Geriatric Oncology*, **2013**, 4, 196-201 3.6

43 Biosimilars in oncology: current and future perspectives. *GaBI Journal*, **2013**, 2, 91-93 3.1 12

42 Importance of monitoring renal function in patients with cancer. *Cancer Treatment Reviews*, **2012**, 38, 235-40 14.4 45

41 Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. *Cancer Treatment Reviews*, **2012**, 38, 120-6 14.4 32

40 Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. *Cancer Treatment Reviews*, **2012**, 38, 815-24 14.4 15

39 Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. *Therapeutic Advances in Urology*, **2012**, 4, 85-101 3.2 10

38 Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. *Therapeutic Advances in Medical Oncology*, **2012**, 4, 95-105 5.4 43

37 SIOG (International Society of Geriatric Oncology) and anthracycline use in the elderly. *European Journal of Cancer, Supplement*, **2011**, 9, 30-35 1.6

36 Delivering affordable cancer care in high-income countries. *Lancet Oncology, The*, **2011**, 12, 933-80 21.7 476

35 Weekly nab-paclitaxel is safe and effective in 65 years old patients with metastatic breast cancer: a post-hoc analysis. *Breast*, **2011**, 20, 468-74 3.6 42

34 Antiemetic research: future directions. *Supportive Care in Cancer*, **2011**, 19 Suppl 1, S49-55 3.9 41

33 Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. *Critical Reviews in Oncology/Hematology*, **2011**, 77, 184-97 7 21

32 Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. *Critical Reviews in Oncology/Hematology*, **2011**, 77, 198-200 7 15

31	Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. <i>Oncologist</i> , 2010 , 15, 1147-58	5.7	33
30	Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?. <i>Supportive Care in Cancer</i> , 2010 , 18, 529-41	3.9	71
29	Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 203-10	7	26
28	Update on erythropoiesis-stimulating agents and clinical trials in oncology. <i>Oncologist</i> , 2009 , 14 Suppl 1, 6-15	5.7	23
27	An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. <i>Oncologist</i> , 2009 , 14 Suppl 1, 1-5	5.7	85
26	Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. <i>European Journal of Cancer</i> , 2009 , 45, 1603-15	7.5	51
25	What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?. <i>European Journal of Cancer</i> , 2009 , 45, 2984-91	7.5	13
24	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. <i>European Journal of Cancer</i> , 2008 , 44, 353-65	7.5	16
23	Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 592-8	2.2	95
22	The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. <i>Supportive Care in Cancer</i> , 2008 , 16, 193-200	3.9	14
21	Overcoming challenges associated with chemotherapy treatment in the senior adult population. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68 Suppl 1, S1-8	7	29
20	International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1832-43	2.2	180
19	Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care. <i>Supportive Care in Cancer</i> , 2007 , 15, 1325-1329	3.9	5
18	Breast cancer in the elderly. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1882-90	2.2	121
17	Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. <i>European Journal of Cancer</i> , 2007 , 43, 510-9	7.5	66
16	International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. <i>European Journal of Cancer</i> , 2007 , 43, 14-34	7.5	198
15	International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. <i>European Journal of Cancer</i> , 2007 , 43, 852-8	7.5	74
14	Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , 2007 , 8, 1101-1115	21.7	270

13	Erythropoietin: effects on life expectancy in patients with cancer-related anaemia. <i>Current Medical Research and Opinion</i> , 2006 , 22, S5-S13	2.5	3
12	Effect of treatment with epoetin Beta on thromboembolic events in anemic patients with cancer: a metaanalysis. <i>Supportive Cancer Therapy</i> , 2006 , 4, 49-55		6
11	Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT ₃ -receptor antagonists in the first 24 hours. <i>Gerontology</i> , 2005 , 51, 287-96	5.5	16
10	5-HT ₃ -receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. <i>Oncology</i> , 2005 , 69, 97-109	3.6	65
9	Optimising antiemetic therapy: what are the problems and how can they be overcome?. <i>Current Medical Research and Opinion</i> , 2005 , 21, 885-97	2.5	29
8	Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 55, 241-52	7	828
7	5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?. <i>Cancer</i> , 2005 , 104, 1-18	6.4	26
6	Evolving treatment strategies for anaemia in cancer: experience with epoetin beta. <i>Oncology</i> , 2004 , 67 Suppl 1, 17-22	3.6	3
5	Granisetron: an update on its clinical use in the management of nausea and vomiting. <i>Oncologist</i> , 2004 , 9, 673-86	5.7	62
4	Treatment for anthracycline-pretreated metastatic breast cancer. <i>Oncologist</i> , 2002 , 7 Suppl 6, 4-12	5.7	45
3	Pharmacology. <i>European Journal of Cancer</i> , 2001 , 37 Suppl 7, S251-2	7.5	60
2	. <i>Annals of Oncology</i> , 2000 , 11, 223-230	10.3	19
1	Methodological issues in antiemetic studies. <i>Investigational New Drugs</i> , 1993 , 11, 243-53	4.3	23